8-K filing — Moleculin Biotech, Inc. (MBRX)
Filed: 2026-08-14 AccNo: 0001437749-26-027835 Size: 380 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 14, 2026, 12:48 PM
- Checked
- Aug 14, 2026, 12:48 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Moleculin Biotech Stock Is Sinking Friday: What's Going On?
Moleculin Biotech updates MIRACLE trial for AML and prices a $9.3M offering at $0.75, driving MBRX shares down 63%. Read full data.
Read original at benzingaMoleculin Biotech shares are trading lower after the company announced it priced a $9.3 million public offering.
Read original at benzinga